A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19

NCT07222384 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

343

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19
SARS-COV-2 Infection

Interventions

BIOLOGICAL: BNT162b2 (2025/2026 formulation)

Sponsor

BioNTech SE

Collaborators

[object Object]